Reacciones en el sitio de inyeccin son las ms frecuentes y afectan aproximadamente al 1-5% de los pacientes segn la informacin de prescripcin de la FDA
Fluctuations in temperature can compromise GLP-1 drugs, rendering them ineffective or potentially harmful
By addressing irritation at its source, KPV polypeptide contributes to a more balanced and resilient system
Patients must be at least 18 years old and meet one of the following clinical requirements when GLP-1 therapy begins: A body mass index, or BMI, of 35 or higher A BMI between 30 and 34.99 with at least one qualifying health condition A BMI between 27 and 29.99 with at least one qualifying higher-risk health condition For someone with a BMI between 30 and 34.99, qualifying conditions may include heart failure with preserved ejection fraction, uncontrolled high blood pressure, stage 3a or higher chronic kidney disease, prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease
also if you experience severe behavioral problems, chest pain or pressure or fast heartbeat, severe dizziness or passing out, nervousness and excitability, or severe headache.
C., Li, S
.png.jpg)
